The effect of propolis dietary supplement on the status of hs-CRP inflammatory index, sex hormone testosterone levels and metabolic profile of women with polycystic ovary syndrome

The effect of propolis dietary supplement consumption on indices of high-sensitivity C-reactive protein, testosterone hormone and metabolic profile in women with polycystic ovary syndrome (PCOS)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121216011763N51

Enrollment

Registered

2021-03-07

Start date

2021-10-08

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Daily consumption of two 350 mg tablets containing 250 mg of propolis extract and 100 mg of safe and ineffective combination of microcrystalline cellulose as a supp

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Diagnosis of PCOS according to Rotterdam criterion: According to this criterion, the subjects should have two of the three diagnostic features of PCOS: 1- Oligomenorrhea and anovulation 2- Hyperandrogenism 3- Polycystic ovary Age between 18 and 45 years Not to have sensitivity to bee products Not to take any specific drug more than metformin Not to have laparoscopic ovarian surgery and assisted reproductive technology

Exclusion criteria

Exclusion criteria: Hormone therapy or taking contraceptive pills (OCP) History of gestational hypertension Pregnancy or breastfeeding Menopause Tobacco and alcohol consumption Having following diseases: Diabetes, cardiovascular, hepatic, renal, thyroid, asthma, neoplasm

Design outcomes

Primary

Measure	Time frame
Homeostatic model assessment of insulin resistance (HOMA-IR). Timepoint: Before study and 12 weeks after supplementation. Method of measurement: formula= (fasting plasma glucose(mmol/l) *fasting insulin (IU/ml))/22.5.	—

Secondary

Measure	Time frame
Testosterone. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Triglyceride. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Cholesterol. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;High density lipoprotein. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Low density lipoprotein. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Fasting blood sugar. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Insulin. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: blood samples by ELISA kits.;Highly sensitive C-reactive protein. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: blood samples by ELISA kits.;Blood pressure. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: barometer.;Weight. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Digital scales.;Waist. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Inelastic meters.;Hip. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Inelastic meters.	—

Measure

Time frame

Testosterone. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Triglyceride. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Cholesterol. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;High density lipoprotein. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Low density lipoprotein. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Fasting blood sugar. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Blood samples by enzymatic method.;Insulin. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: blood samples by ELISA kits.;Highly sensitive C-reactive protein. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: blood samples by ELISA kits.;Blood pressure. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: barometer.;Weight. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Digital scales.;Waist. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Inelastic meters.;Hip. Timepoint: Before study and 12 weeks after supplementation. Method of measurement: Inelastic meters.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Askari

Esfahan University of Medical Sciences

askari@mui.ac.ir+98 31 3792 3171

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026